The University of Chicago Header Logo

Connection

Gini Fleming to Carcinoma, Transitional Cell

Back to Details
This is a "connection" page, showing publications Gini Fleming has written about Carcinoma, Transitional Cell.
Gini Fleming
Connection Strength
0.033
Carcinoma, Transitional Cell
  1. Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies. Gynecol Oncol. 2018 03; 148(3):507-514.
    View in: PubMed
    Score: 0.033
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.